ЕФЕКТИВНІСТЬ АВТОЛОГІЧНОЇ ТРАНСПЛАНТАЦІЇ СТОВБУРОВИХ КЛІТИН У ДОРОСЛИХ ІЗ ЛІМФОМОЮ БЕРКІТТА АБО БЕРКІТТ-ПОДІБНОЮ ЛІМФОМОЮ: СИСТЕМАТИЧНИЙ ОГЛЯД

• Datum: 2023
• Hauptverfasser: Joshi, U., Subedi, R., Nepal, G., Gyawali, S., Agrawal, V., Poudyal, B.S., Bhatt, V.R., D’Angelo, Ch.R.
• Format: Artikel
• Sprache: English
• Veröffentlicht: PH Akademperiodyka 2023
• Schlagworte: лімфома Беркітта; хіміотерапія; транс­плантація гемопоетичних стовбурових клітин аутологічна; виживаність.
• Online Zugang: https://exp-oncology.com.ua/index.php/Exp/article/view/2022-3-14
• Назва журналу: Experimental Oncology

Background: Burkitt and Burkitt like lymphoma (BL/BLL) are highly proliferative germinal or post-germinal B cell tumors. Few studies have evaluated the impact of autologous stem cell transplantation (ASCT) on disease outcomes. Aim: We performed a systematic review to analyze the efficacy of ASCT as frontline consolidation and for treatment of relapsed/refractory cases in adult BL/BLL. Materials and Methods: Eligible studies with clear outcome measures on the efficacy of ASCT in adult patients with BL/BLL were identified through systematic search. The overall survival (OS), progression-free survival (PFS), complete response (CR), partial response (PR), and progression/relapse were used to assess the efficacy. Results: For patients who underwent ASCT in first CR, 5-year PFS and OS ranged between 70–78% and 70–83% respectively. For relapsed/refractory disease, 5-year PFS and OS were 27% and 31%, respectively. Patients undergoing ASCT for chemoresistant disease fared poorly with 3-year OS of 7% vs 37% for chemosensitive disease (p ≤ 0.00001). The overall response rate to ASCT for patients transplanted in first CR ranged between 71% and 93% and was 37% for patients who were transplanted in disease status other than first CR. Disease progression/relapse was observed in 16–29% of the patients transplanted in first CR, and 55% to 60% in relapsed disease. Conclusion: We found insufficient evidence to support ASCT over chemotherapy alone in the first remission for adult BL/BLL. Evidence supports guidelines recommending ASCT for chemosensitive disease but suggests there is no benefit to ASCT for chemoresistant disease.